General Archives - Gilde Healthcare

latest
news

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete Concentric Collapse (“CCC”). DEKRA attributed the updated Genio® therapeutic indication to...
October 5, 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert and former Chief Executive Officer of Sage Therapeutics, with more than 25 years of experience in the pharmaceutical and healthcare […]

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted, validated and is now under formal review in […]

Gilde Healthcare appoints Joep Muijrers to lead investments in public markets

Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, today announced the appointment of Dr. Joep Muijrers to the investment team of its Venture & Growth capital fund. Joep will be responsible for Gilde’s investments in publicly-traded companies focused on therapeutics, healthtech and medical devices...

Gilde Healthcare raises €416 million ($450 million) venture and growth capital fund

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Gilde Healthcare today announces the first and final close of Gilde Healthcare V, a €416 million ($450 million) venture and growth capital fund. The new fund, which was oversubscribed, targets growth opportunities in a broad range of healthcare sectors including...

Gilde Healthcare raises €200 million for new private equity fund

Targeting lower mid-market healthcare investments in the Benelux and DACH regions Utrecht (the Netherlands) and Frankfurt (Germany) – Gilde Healthcare, the European specialist investor in healthcare, today announces that it has raised €200 million for its third private equity fund, Gilde Healthcare Services III. The fund will...

Gilde Healthcare opens office in Frankfurt Germany

Utrecht, the Netherlands and Frankfurt am Main, Germany – Gilde Healthcare, the European specialist healthcare investor is pleased to announce the opening of its office in Frankfurt am Main, Germany. The Frankfurt office will focus on healthcare service providers and suppliers headquartered in Germany, Austria and Switzerland...

Private Equity Looking for Interns

Gilde Healthcare Services, a lower mid-market buy-out fund focused on Benelux and Germany, is looking for a student intern that is able to support the investment team with its activities. Given the compact investment team, the intern will have the opportunity to take an integral role in...

Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund

New fund targets innovative scale-up opportunities in medtech, digital health and therapeutics Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million ($285 million) later stage and growth capital fund. The...
Loading...
These were all messages
be1a211309